Spanish Pharmaceutical Company Choose IDBS to Improve Drug Discovery
News Nov 02, 2005
IDBS has announced the latest implementation of their flagship product, ActivityBase. J.Uriach (Barcelona, Spain) plan to improve their current developmental focus on inflammatory diseases through the deployment of the ActivityBase solution.
Dr. Elena Carceller, Head of Medicinal Chemistry for J.Uriach said, "Our Company has grown significantly during its long and prestigious history. This growth has presented us with new challenges regarding the day-to-day management of results. We needed a solution that was scalable to our needs, but also one which was proven within the industry – which is why we chose IDBS."
IDBS first began discussing J.Uriach's requirements back in 2003, where they established a clear requirement for one integrated platform to handle the biological, chemical and statistical data generated by the laboratory.
IDBS consultants determined how current information could be ported to the new ActivityBase environment, and how the new architecture could be applied to the current J.Uriach workflow.
This consultative approach prompted Dr. Robert Soliva, Project Manager for J.Uriach to comment, "Rather than simply sell us a product, we were impressed with the professional approach IDBS adopted to ensure we had a solution that was precisely suited to our requirements."
Mr. Neil Kipling, Founder, Chairman and CEO for IDBS said, "we have remained at the forefront of drug discovery data management for well over a decade now. It is deeply gratifying to know that major pharmaceutical companies continue to recognise the value our products deliver. IDBS view Spain as a significant emerging market for both biotech and pharmaceutical companies, and take great pride in serving such a high percentage of those companies."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE